The Lancet. Neurology

How common sleep problems and sleep medication use are in astronauts before, during, and after spaceflight

Updated

Abstract

Data from 64 astronauts on 80 space shuttle missions and 21 astronauts on 13 ISS missions revealed significant sleep deprivation during spaceflight.

  • Astronauts attempted an average of 7.35 hours of sleep per night on space shuttle missions but only obtained 5.96 hours.
  • During ISS missions, astronauts obtained an average of 6.09 hours of sleep while in space.
  • Sleep duration was significantly less during the 11 days before spaceflight and 3 months prior compared to the first week post-mission.
  • Approximately 78% of shuttle-mission crew members and 75% of ISS crew members reported using sleep-promoting drugs.
  • Chronic sleep loss during space missions may be linked to performance decrements, highlighting the need for effective sleep countermeasures.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Conflicts of Interest . Dr. Barger has previously received research support from Cephalon, Inc., non-public sponsors of research. She consults for Alertness Solutions and San Jose State University Foundation. Dr. Flynn-Evans is now an employee of NASA Ames Research Center. This research was completed before she moved from Brigham and Women’s Hospital to NASA Ames.. Dr. Kubey has a patent, REM-Sleep Directed Visual Alarm System and Method, issued. Dr. Walsh reports grants from Fujitsu Ireland and personal fees from Irish Centre for Manufacturing Research, outside the submitted work. Mr. Ronda has nothing to disclose. Dr. Wang has no conflicts to report. Dr. Wright reports grants from NASA, during the conduct of the study; grants from Philips, Inc, personal fees from Takeda Pharmaceuticals, personal fees from Zeo, Inc, personal fees from Northwestern University American Waterways Operators Towboat Project, outside the submitted work. Dr. Czeisler has received consulting fees from or served as a paid member of scientific advisory boards for: Teva Pharmaceutical Industries Ltd.; Koninklijke Philips Electronics, N.V.; Purdue Pharma LP; and Vanda Pharmaceuticals, Inc. Dr. Czeisler owns an equity interest in Vanda Pharmaceuticals, Inc. and receives royalties and research support from Philips Respironics, Inc. The Harvard Medical School Sleep and Health Education Program has received Educational Grant funding from Cephalon, Inc., Takeda Pharmaceuticals, Sanofi-Aventis, Inc. and Sepracor, Inc. Dr. Czeisler is the incumbent of an endowed professorship provided to Harvard University by Cephalon, Inc. and holds a number of process patents in the field of sleep/circadian rhythms (e.g., photic resetting of the human circadian pacemaker). Since 1985, Dr. Czeisler has also served as an expert witness on various legal cases related to sleep and/or circadian rhythms.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free